We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 19, 2021

Long-Term OS and Predictors in Anti–PD-1–Naive Patients With Melanoma and Brain Metastases Treated With ICIs

Journal of Immunotherapy (Hagerstown, Md. : 1997)


Additional Info

Journal of Immunotherapy (Hagerstown, Md. : 1997)
Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study
J. Immunother. 2021 Oct 01;44(8)307-318, GS Naik, EI Buchbinder, JV Cohen, MP Manos, AEW Johnson, P Bowling, AA Aizer, JD Schoenfeld, DP Lawrence, R Haq, FS Hodi, RJ Sullivan, PA Ott

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading